Elsevier

Blood Reviews

Volume 44, November 2020, 100672
Blood Reviews

Review
Targeting MCL-1 in hematologic malignancies: Rationale and progress

https://doi.org/10.1016/j.blre.2020.100672Get rights and content
Under a Creative Commons license
open access

Abstract

Myeloid cell leukemia sequence 1 (MCL-1) is an antiapoptotic protein that plays a key role in promoting cell survival in multiple myeloma (MM), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Overexpression of MCL-1 is associated with treatment resistance and poor prognosis; thus, MCL-1 inhibitors are rational therapeutic options for malignancies depending on MCL-1. Several MCL-1 inhibitors have entered clinical trials, including AZD5991, S64315, AMG 176, and AMG 397. A key area of investigation is whether MCL-1 inhibitors will complement the activity of BCL-2 inhibitors, such as venetoclax, and synergistically enhance anti-tumor efficacy when given in combination with other anti-cancer drugs. Another important question is whether a safe therapeutic window can be found for this new class of inhibitors. In summary, inhibition of MCL-1 shows potential as a treatment for hematologic malignancies and clinical evaluation of MCL-1 inhibitors is currently underway.

Keywords

MCL-1 inhibitor
Multiple myeloma
Acute myeloid leukemia
Non-Hodgkin lymphoma
BH3-mimetic

Cited by (0)

1

These authors contributed equally to the work.